Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Metabolomics Biomarkers of Prostate Cancer: A Systematic Review.

Kdadra M, Höckner S, Leung H, Kremer W, Schiffer E.

Diagnostics (Basel). 2019 Feb 19;9(1). pii: E21. doi: 10.3390/diagnostics9010021. Review.

2.

Translational Metabolomics of Head Injury: Exploring Dysfunctional Cerebral Metabolism with Ex Vivo NMR Spectroscopy-Based Metabolite Quantification.

Wolahan SM, Hirt D, Glenn TC.

In: Kobeissy FH, editor. Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects. Boca Raton (FL): CRC Press/Taylor & Francis; 2015. Chapter 25.

3.

Prostate cancer diagnosis and characterization with mass spectrometry imaging.

Kurreck A, Vandergrift LA, Fuss TL, Habbel P, Agar NYR, Cheng LL.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):297-305. doi: 10.1038/s41391-017-0011-z. Epub 2017 Dec 5. Review.

4.

Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence.

Kelly RS, Vander Heiden MG, Giovannucci E, Mucci LA.

Cancer Epidemiol Biomarkers Prev. 2016 Jun;25(6):887-906. doi: 10.1158/1055-9965.EPI-15-1223. Epub 2016 Apr 6. Review.

5.

Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies.

Lima AR, Bastos Mde L, Carvalho M, Guedes de Pinho P.

Transl Oncol. 2016 Aug;9(4):357-70. doi: 10.1016/j.tranon.2016.05.004. Review.

6.

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PMID:
30843003
7.

Multiparametric MRI in detection and staging of prostate cancer.

Boesen L.

Dan Med J. 2017 Feb;64(2). pii: B5327. Review.

PMID:
28157066
8.

The Potential of MicroRNAs as Prostate Cancer Biomarkers.

Fabris L, Ceder Y, Chinnaiyan AM, Jenster GW, Sorensen KD, Tomlins S, Visakorpi T, Calin GA.

Eur Urol. 2016 Aug;70(2):312-22. doi: 10.1016/j.eururo.2015.12.054. Epub 2016 Jan 22. Review.

9.

NMR-based metabolomics studies of human prostate cancer tissue.

Lima AR, Pinto J, Bastos ML, Carvalho M, Guedes de Pinho P.

Metabolomics. 2018 Jun 18;14(7):88. doi: 10.1007/s11306-018-1384-2. Review.

PMID:
30830350
10.

Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literature.

Abrate A, Lughezzani G, Gadda GM, Lista G, Kinzikeeva E, Fossati N, Larcher A, Dell'Oglio P, Mistretta F, Buffi N, Guazzoni G, Lazzeri M.

Korean J Urol. 2014 Jul;55(7):436-45. doi: 10.4111/kju.2014.55.7.436. Epub 2014 Jul 11. Review.

11.

Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review.

van den Bergh RC, Ahmed HU, Bangma CH, Cooperberg MR, Villers A, Parker CC.

Eur Urol. 2014 Jun;65(6):1023-31. doi: 10.1016/j.eururo.2014.01.027. Epub 2014 Jan 28. Review.

PMID:
24491309
12.

Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach.

Alberice JV, Amaral AF, Armitage EG, Lorente JA, Algaba F, Carrilho E, Márquez M, García A, Malats N, Barbas C.

J Chromatogr A. 2013 Nov 29;1318:163-70. doi: 10.1016/j.chroma.2013.10.002. Epub 2013 Oct 4.

PMID:
24139504
13.

Metabolomics Biomarkers for Detection of Colorectal Neoplasms: A Systematic Review.

Erben V, Bhardwaj M, Schrotz-King P, Brenner H.

Cancers (Basel). 2018 Jul 27;10(8). pii: E246. doi: 10.3390/cancers10080246. Review.

14.

Novel diagnostic biomarkers of prostate cancer: an update.

Anceschi U, Tuderti G, Lugnani F, Biava PM, Malossini G, Luciani L, Cai T, Marsiliani D, Filianoti A, Mattevi D, Costantini M, Misuraca L, Simone G.

Curr Med Chem. 2018 Sep 13. doi: 10.2174/0929867325666180914115416. [Epub ahead of print]

PMID:
30215331
15.

Clinical use of novel urine and blood based prostate cancer biomarkers: a review.

Dijkstra S, Mulders PF, Schalken JA.

Clin Biochem. 2014 Jul;47(10-11):889-96. doi: 10.1016/j.clinbiochem.2013.10.023. Epub 2013 Oct 29. Review.

PMID:
24177197
16.

Use of two gene panels for prostate cancer diagnosis and patient risk stratification.

Xiao K, Guo J, Zhang X, Feng X, Zhang H, Cheng Z, Johnson H, Persson JL, Chen L.

Tumour Biol. 2016 Aug;37(8):10115-22. doi: 10.1007/s13277-015-4619-0. Epub 2016 Jan 28.

PMID:
26820133
17.

Genomic Markers in Prostate Cancer Decision Making.

Cucchiara V, Cooperberg MR, Dall'Era M, Lin DW, Montorsi F, Schalken JA, Evans CP.

Eur Urol. 2018 Apr;73(4):572-582. doi: 10.1016/j.eururo.2017.10.036. Epub 2017 Nov 10. Review.

PMID:
29129398
18.

Current Trends in Cancer Biomarker Discovery Using Urinary Metabolomics: Achievements and New Challenges.

Burton C, Ma Y.

Curr Med Chem. 2019;26(1):5-28. doi: 10.2174/0929867324666170914102236. Review.

PMID:
28914192
19.

Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease.

Neuhaus J, Schiffer E, von Wilcke P, Bauer HW, Leung H, Siwy J, Ulrici W, Paasch U, Horn LC, Stolzenburg JU.

PLoS One. 2013 Jun 24;8(6):e67514. doi: 10.1371/journal.pone.0067514. Print 2013.

20.

Supplemental Content

Support Center